# Trends and racial/ethnic differences in opioid prescribing safety and use of nonpharmacologic treatments for chronic pain in adults with co-occurring opioid use disorder

> **NIH NIH P20** · BROWN UNIVERSITY · 2021 · $184,471

## Abstract

In the climate of increased opioid-related morbidity and mortality in the U.S., the safe, effective and 
comprehensive management of chronic pain is critically important. People with comorbid chronic pain and 
OUD and racial and ethnic minorities deserve specific attention due to their potential under-treatment of 
pain and OUD, and elevated risk of adverse health outcomes. In 2016, the Centers for Disease Control 
and Prevention (CDC) released a prominent clinical practice guideline that emphasizes non-opioid and 
non-drug alternatives for pain management, and recommends safer prescribing practices if opioids are 
prescribed to treat chronic pain. An examination of chronic pain treatment patterns over time and in 
vulnerable subgroups of minorities and people with co-occurring OUD is needed to understand and 
address health disparities in the delivery of guideline concordant treatment for chronic pain. Using 2015 to 
2018 Medicare enrollment data combined with inpatient, outpatient and prescription claims data from a 
20% national sample, the proposed research aims to: (1) assess racial and ethnic disparities in the types 
of chronic pain treatments provided to people with comorbid OUD, and (2) evaluate whether the 
implementation of the CDC guideline influenced racial/ethnic disparities in the treatment of chronic pain 
for those with OUD. We will categorize pain treatments as pharmacologic, non-pharmacologic, and 
combination of pharmacologic and non-pharmacologic. Among those prescribed opioids, we will assess 
the guideline concordance of prescribing as it relates to opioid dosage and concurrent benzodiazepine 
prescriptions. We hypothesize that racial/ethnic minorities with OUD are less likely to receive guideline 
concordant opioid management and non-drug therapy than White chronic pain patients with OUD. We 
further anticipate worsened disparities in chronic pain treatment following release of the CDC opioid 
guideline. If confirmed, we will explore potential sources of disparities (e.g., co-prescribing of naloxone, 
involvement of pain and addiction specialists) that could inform interventions to improve chronic pain 
treatment in those with cooccurring OUD. The long-term goal of this research is to characterize and 
reduce disparities in receipt of recommended standards of care and evidence-based treatment for people 
with co-occurring chronic pain and OUD. Our findings will provide much needed evidence for more 
effective and equitable public health and health insurance policy, and can inform future clinical guidelines.

## Key facts

- **NIH application ID:** 10488981
- **Project number:** 5P20GM130414-03
- **Recipient organization:** BROWN UNIVERSITY
- **Principal Investigator:** Patience Moyo Dow
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $184,471
- **Award type:** 5
- **Project period:** 2021-08-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10488981

## Citation

> US National Institutes of Health, RePORTER application 10488981, Trends and racial/ethnic differences in opioid prescribing safety and use of nonpharmacologic treatments for chronic pain in adults with co-occurring opioid use disorder (5P20GM130414-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10488981. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*